## Venture Capital

2019

2019: Emerging companies and leading venture capitalists turn to WilmerHale for legal advice and business advantage. Thousands of startups have relied on us from formation to funding to business expansion, with many going on to achieve market leadership and successful IPOs or acquisitions. In 2018, we served as counsel in more than 200 venture financings raising close to \$4.5 billion, including some of the largest and most prominent deals of the year. Since 2008, we have handled approximately 2,800 venture financings with total proceeds in excess of \$39 billion. We have one of the top venture capital practices in the country, and over the past decade have represented more venture capital—backed companies in the eastern half of the United States than any other law firm. The following is a selection of our recent venture capital transactions.



## Counsel of Choice for Venture Capital Financings

Serving industry leaders in technology, life sciences, cleantech, financial services, communications and beyond



generation bio

SCHRÖDINGER.

Carisma THERAPEUTICS

RIGUP

PANDION THERAPEUTICS tvardi. § Cedar

Constellation PHARMACEUTICALS

\$100,000,000 Second Round February 2018 \$85,000,000 *Late Stage*November 2018

\$53,000,000

First Round
June 2018

\$60,000,000

Third Round
October 2018

\$58,000,000

First Round

January 2018

\$9,000,000

First Round

June 2018

\$36,000,000 Second Round June 2018

\$100,000,000 Late Stage

March 2018

ALTIOSTAR

\$32,000,000

Late Stage

January 2018

ribomotrix

\$30,000,000

First Round

November 2018

A I M M U T A

\$20,000,000 Second Round June 2018



\$18,000,000

Third Round
September 2018

Decibel

\$55,000,000 Third Round May 2018



\$65,000,000 Second Round December 2018 disam THERAPEUTICS

\$30,000,000

First Round

August 2017

UNTUCKit

\$30,000,000

First Round

June 2017

\$34,000,000

First Round
September 2017

Cydan

BIOCATCH

tion • Less Fraud

\$30,000,000 Second Round March 2018 YOSHI

\$13,700,000

First Round

December 2017

affirmed<sup>®</sup>

\$38,000,000 *Late Stage*February 2019

**@**apella Space

\$19,000,000 Second Round August 2018 STASH

\$37,500,000

Fourth Round
January 2018

CAPE

\$17,000,000 Second Round June 2018 Reach Labs

\$9,000,000

First Round

August 2018

Fulcrum
Therapeutics

\$80,000,000 Second Round August 2018

RIGHTHAND

\$23,000,000 Second Round

December 2018

NanoView BIOSCIENCES

> \$10,000,000 Second Round September 2018

Acumatica

The Cloud ERP

\$25,000,000

Third Round

June 2018

[c] Dedrone

\$16,000,000

Third Round
September 2018

CRUX

\$20,000,000 Second Round September 2018 **OBlueVine** 

\$60,000,000 Late Stage May 2018 **ZAIUS** 

\$30,000,000 Second Round March 2018 **Q** Curai

\$10,700,000 Second Round February 2018 **NANTERO** 

\$29,700,000 *Late Stage* April 2018















Connect with us in



